A retrospective database analysis comparing readmission rates among patients hospitalized for chronic obstructive pulmonary disease (COPD) who were treated with nebulized arformoterol tartrate compared to inhaled tiotropium

Trial Profile

A retrospective database analysis comparing readmission rates among patients hospitalized for chronic obstructive pulmonary disease (COPD) who were treated with nebulized arformoterol tartrate compared to inhaled tiotropium

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Arformoterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2015 New trial record
    • 19 Oct 2015 According to a Sunovion media release, results from this trial will be presented at the 2015 American College of Chest Physicians annual meeting (CHEST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top